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Abstract 
Background: Transfusion-transmitted malaria (TTM) is a well-recognized risk of receiving blood transfusions, and 
has occurred with Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. The simian 
parasite Plasmodium knowlesi is also known to be transmissible through inoculation of infected blood, and this spe-
cies is now the most common cause of malaria in Malaysia with a high rate of severity and fatal cases reported. No 
confirmed case of accidental transfusion-transmitted P. knowlesi has yet been reported.
Case presentation: A 23-year old splenectomized patient with beta thalassaemia major presented with fever 
11 days after receiving a blood transfusion from a pre-symptomatic donor who presented with knowlesi malaria 
12 days following blood donation. The infection resulted in severe disease in the recipient, with a parasite count of 
84,000/µL and associated metabolic acidosis and multi-organ failure. She was treated with intravenous artesunate 
and made a good recovery. Sequencing of a highly diverse 649-base pair fragment of the P. knowlesi bifunctional 
dihydrofolate reductase-thymidylate synthase gene (pkdhfr) revealed that the recipient and donor shared the same 
haplotype.
Conclusions: This case demonstrates that acquisition of P. knowlesi from blood transfusion can occur, and that clini-
cal consequences can be severe. Furthermore, this case raises the possibility that thalassaemic patients, particularly 
those who are splenectomized, may represent a high-risk group for TTM and severe malaria. With rising P. knowlesi 
incidence, further studies in Sabah are required to determine the risk of TTM in order to guide screening strategies for 
blood transfusion services.
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Background
Transfusion-transmitted malaria (TTM) was first 
described in 1911 [1] and remains an important pub-
lic health problem. In non-endemic countries, stringent 
screening processes have led to a very low incidence, with 
less than one case occurring per one million donations 
[2], however, clinical consequences can be severe due to 
lack of background immunity in the population [2, 3]. In 
endemic countries, the incidence of TTM is substantially 
higher due to a high prevalence of parasitaemia among 
blood donors; a systematic review in sub-Saharan Africa 
reported a median prevalence of parasitaemia among 
blood donors of 10.2  % (range 2–55  %) [4]. In endemic 
countries outside sub-Saharan Africa, malaria prevalence 
among blood donors is generally lower [5, 6], however 
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risk of acquiring malaria from infected blood may be 
higher due to the lower immunity of recipients.
TTM has been reported to occur as a result of infection 
with Plasmodium falciparum, Plasmodium vivax, Plas-
modium malariae, and Plasmodium ovale [7, 8], and one 
probable case of transfusion-transmitted Plasmodium 
knowlesi has been reported [9]. In Sabah, Malaysian Bor-
neo, the overall incidence of clinical malaria is low, and 
population immunity likely minimal, however human 
cases of P. knowlesi are increasing, with the species now 
the most common cause of malaria in Sabah [10]. Plas-
modium knowlesi has a 24-hour erythrocytic life cycle, 
and high parasitaemias can develop rapidly. In adults, the 
risk of severe disease is at least as high as that of P. falci-
parum [11], and fatal cases have been reported [10, 12–
18]. Transfusion-transmitted P. knowlesi may therefore 
constitute a significant risk in knowlesi-endemic areas 
such as Sabah.
Current screening practices in Sabah include a pre-
donation questionnaire to exclude donors with history of 
fever in the previous 7  days, and microscopic examina-
tion of a thick and thin blood film for malaria parasites. 
Microscopy, however, fails to detect parasitaemias <50/
µL [19], and for P. falciparum it has been established 
that as few as ten parasites per unit of red blood cells 
are sufficient to transmit infection [20]. Screening with 
microscopy does not therefore eliminate the risk of TTM. 
Recently, the first reported Malaysian case of TTM was 
described, involving a child in West Malaysia infected 
with P. vivax from a donor recently returned from Myan-
mar [21]. Although P. knowlesi is well known from early 
experimental and neurosyphilis studies to be transmis-
sible through inoculation of infected blood [22, 23], no 
confirmed case of accidental transfusion-transmitted P. 
knowlesi has yet been reported.
This report describes a case of severe transfusion-
transmitted P. knowlesi infection in a splenectomized 
thalassaemic patient, acquired from a pre-symptomatic 
donor who presented with knowlesi malaria soon after 
donation.
Case presentation
A 23-years old female presented to Pitas District Hospi-
tal in northeast Sabah, Malaysia, with a 5-day history of 
fever, rigours, headache, and dizziness. She lived with her 
family in a malaria-endemic village surrounded by palm 
oil plantations, where long-tailed macaques were regu-
larly seen. She had a history of beta thalassaemia major, 
diagnosed at 9 months of age and requiring splenectomy 
at age 13  years. She received iron chelation and second 
monthly blood transfusions at her local hospital. Her last 
blood transfusion had been 16 days prior to presentation, 
and her post-transfusion haemoglobin was 9.8 g/dL. She 
had recently commenced oral hypoglycaemic agents for 
type 2 diabetes mellitus.
On presentation at the district hospital her vital signs 
were within normal range, including an oxygen satura-
tion of 98  %. Her haemoglobin was 8.7  g/dL, white cell 
count 48  ×  103/µL and platelet count 129  ×  103/µL. 
She was admitted with a provisional diagnosis of symp-
tomatic anaemia. Later that day she developed res-
piratory distress with an oxygen saturation of 50  % on 
room air, improving to 72  % on high-flow oxygen, and 
she was transferred to a tertiary referral hospital in the 
state capital, Kota Kinabalu. On arrival her temperature 
was 38.6  °C, heart rate 139 beats/min, blood pressure 
116/69 mm Hg, and oxygen saturation 93 % on high-flow 
mask with a respiratory rate of 36 breaths per minute. 
A blood film taken on arrival was positive for malaria 
parasites resembling P. knowlesi, with a parasite count 
of 84,000 parasites/µL. Further investigation revealed 
worsening anaemia (haemoglobin 6.0  g/dL) and further 
elevation of the white blood cell count (61  ×  103/µL), 
in addition to metabolic acidosis (lactate 16  mmol/L, 
bicarbonate 8.4  mmol/L, pH 7.14), hyperbilirubinemia 
(80 µmol/L), acute kidney injury (creatinine 184 µmol/L), 
increased liver transaminases (alanine transaminase 
181 U/L and aspartate transaminase 308 U/L), and hypo-
glycaemia (blood glucose 2.5  mmol/L) (Table  1). Chest 
radiograph was initially unremarkable, however, on day 
1 showed mild bilateral interstitial infiltrates. She was 
diagnosed with severe knowlesi malaria, admitted to 
the intensive care unit, and commenced on intravenous 
artesunate, intravenous antibiotics (initially piperacillin/
tazobactam, then ceftriaxone) and inotropic support; 
she was transfused two units of whole blood. She made 
a good recovery, and on day 2 after completing three 
doses of intravenous artesunate, she was changed to 
oral artemether-lumefantrine (Riamet®) for 3  days and 
discharged from the intensive care unit. Her blood film 
was negative for malaria parasites on day 3, and she was 
discharged from hospital on day 9. Dengue NS1 antigen 
and blood cultures taken prior to antibiotics were nega-
tive. PCR of her initial blood sample using previously 
described methods [24] confirmed P. knowlesi.
Donor
In view of the patient’s blood transfusion 16  days prior 
to admission, the possibility of transfusion-acquired 
P. knowlesi was investigated. The blood bank was con-
tacted for information regarding the donor, the donor 
was informed, and donation records were obtained from 
the blood bank. Medical records of the donor were sub-
sequently retrieved from Pitas District Hospital where he 
had been admitted, and reviewed for clinical and labora-
tory details. An EDTA blood sample was retrieved from 
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the State Public Health Laboratory, where it had been 
sent for Plasmodium PCR.
The blood donor was a 51-years old male farmer who 
lived in a malaria-endemic village 3  h drive from the 
patient’s village, and who had donated blood 4 days prior 
to the patient’s blood transfusion. He was well on the day 
of the blood donation, and a screening blood film was 
negative for malaria parasites. Twelve days following the 
donation however, he was admitted to the same district 
hospital with a 5-day history of fever, chills, headache, 
nausea, and malaise. His blood film was reported as P. 
falciparum ‘2+’ (indicating 40-400 parasites/µL). He was 
treated with oral artesunate and mefloquine (Artequin®) 
for uncomplicated malaria, and was discharged after 
4  days. PCR performed on an admission EDTA blood 
sample confirmed P. knowlesi.
Molecular analysis
Molecular finger-printing of the patient and donor infec-
tions was undertaken using sequence data generated on 
a 649-base pair fragment of the P. knowlesi bifunctional 
dihydrofolate reductase-thymidylate synthase gene (pkd-
hfr, PKNH_0509600), which has been demonstrated to be 
highly diverse in Sabah [25]. DNA extraction and pkdhfr 
sequencing was conducted using the methods described 
by Grigg et al. [25]. Additional pkdhfr sequence data on 
21 P. knowlesi infections sourced from the same district 
were retrieved from Grigg et al. to assess the local pkdhfr 
diversity. Analysis using DnaSP (version 5.10.01) con-
firmed high diversity amongst the 22 baseline samples. A 
total of 18 distinct haplotypes were observed, with haplo-
type diversity estimated at 0.978 (i.e., approximately 2 % 
probability that two independent infections randomly 
selected from the population would have identical haplo-
types by chance alone). The patient and donor infections 
shared the same haplotype along with one other infection 
(QEM131) (Fig. 1).
Discussion
This report describes a case of severe transfusion-trans-
mitted knowlesi malaria, the occurrence of which may 
have implications for blood transfusion practices in 
knowlesi-endemic areas. Plasmodium knowlesi is the 
most common cause of malaria in Malaysia [10, 26, 27], 
and the species may cause severe and fatal disease [10, 
12]. Cases of transfusion-transmitted falciparum malaria 
can rapidly be fatal in susceptible individuals [28]. Trans-
fusion-transmitted P. knowlesi may represent a significant 
risk in endemic areas, particularly in those at high risk, 
such as the asplenic thalassaemic patient described in 
this report.
The risk of being exposed to P. knowlesi through blood 
transfusion in Sabah is difficult to estimate. Although no 
cross-sectional prevalence survey has yet been reported 
in Sabah, a recent molecular-based survey of individuals 
residing in households or villages of symptomatic malaria 
Table 1 Laboratory investigations
APTT activated partial thromboplastin time
a Investigation results from referral hospital
b Post blood transfusion
Day 0a Day 1 Day 2 Day 3 Day 4 Day 5 Day 7
Parasite count (parasites/µL) 84,000 22,667 313 0 0 0 0
Haemoglobin (g/dL) 6.0 11.7b 9.9 9.7 9.0 7.4 11.9b
Haematocrit (%) 17.9 33.4b 27.6 27.2 24.9 20.6 34.0b
White blood cells (×103/µL) 61 27 28 26 24 20 26
Platelets (×103/µL) 96 70 36 83 126 191 413
Creatinine (µmol/L) 184 127 52 63 63 48 60
Urea (mmol/L) 7.7 11.3 7.6 7.5 4.7 2.8 202
Sodium (mmol/L) 125 129 127 126 128 132 129
Potassium (mmol/L) 2.6 4.5 4.1 4.0 3.8 2.9 4.0
Bilirubin (µmol/L) 80 110 93 63 48 41 37
Lactate (µmol/L) 16 4.8 1.3
Bicarbonate (mmol/L) 8.4 19.7 16.5
Alanine transferase (IU/L) 181 236 168 136 83 70 55
Aspartate transferase (IU/L) 308 322 149 108 78 91 75
Glucose (mmol/L) 2.5 10.8
Prothrombin time (seconds) 37.4 18.5 15.7
APTT (seconds) 78.7 51.8 42.7
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patients in northeast Sabah found that in this popula-
tion the prevalence of asymptomatic P. knowlesi infection 
was 6.9 % [29]. In a recent study in Ghana, where 55 % 
of blood donors were parasitaemic when tested by PCR, 
the incidence of TTM in non-parasitaemic recipients 
receiving parasitaemic blood was around 14–28  % [30]. 
The risk of acquiring malaria from infected blood may 
be higher in Sabah where immunity of the population is 
likely to be low.
Beta thalassaemia has been shown to be a risk factor 
for other severe infections, with increasing risk associ-
ated with duration of thalassaemia, number of trans-
fusions, previous splenectomy, and receiving the iron 
chelator deferoxamine [31]. Additional factors thought 
to contribute to infection risk include anaemia, reticulo-
endothelial dysfunction resulting from iron overload and 
haemolysed erythroblasts, and altered immune responses 
[32]. The incidence of TTM among thalassaemic patients 
in endemic countries is difficult to quantify, as recipients 
frequently have pre-existing parasitaemia [20]. In a study 
in Sri Lanka, a higher frequency of P. vivax antibodies 
was found in thalassaemia patients compared to age-
matched controls, with frequency particularly high in 
splenectomized patients [33]. An Indian study demon-
strated post-transfusion malaria occurring in 6.4  % of 
beta thalassaemia patients who received repeated blood 
transfusion [34]. Malaysia has a high prevalence of thalas-
saemia; in 2009 there were 4541 registered thalassaemia 
patients, of whom 3310 were transfusion-dependent with 
either beta thalassaemia major or HbE beta thalassaemia. 
The state of Sabah has the highest number of registered 
thalassaemia cases, accounting for 28 % of the total cases 
in Malaysia [35]. TTM among the beta thalassaemia 
population in malaria-endemic regions of Sabah may be 
under-reported and requires further investigation.
In addition to being a possible risk factor for TTM, 
the lack of a spleen has been associated with severe 
malaria following infection with P. falciparum [36], and 
severe knowlesi malaria in splenectomized patients has 
also been reported [11, 37]. High parasite counts and 
severe disease, as occurred in this case, usually occur in 
older patients, being relatively uncommon among young 
patients with knowlesi malaria [11]. Over 100 cases of 
severe knowlesi malaria have now been reported [10–
17, 37–44]; to our knowledge, only 6 cases have been 
reported in patients <30 years old [11, 13, 37], with only 
2 of these having more than one severity criteria [13, 37]. 
Notably, the only previous report of multi-organ failure 
in a patient <30 years old occurred in a splenectomized 
patient [37]. It is therefore possible that in this 23-years 
old patient the lack of spleen contributed to her severe 
disease. Furthermore, direct inoculation of P. knowlesi-
infected blood may have contributed to the development 
of severe disease; early studies from the neurosyphilis 
era demonstrated increased virulence of infection with 
serial blood passage through humans [45, 46], and more 
recently in a murine model parasite, virulence was found 
to be modified by vector transmission [47].
To reduce the risk of TTM in endemic countries the 
World Health Organization recommends several strat-
egies, including donor selection and deferral, and/or 
screening of all donated blood for malaria parasites [48]. 
However, current screening strategies are associated with 
significant limitations. In Sabah, microscopy is used as 
the current screening policy, however it has poor sen-
sitivity for low parasitaemias [29], and hence will fail to 
detect a significant proportion of sub-clinical infections, 
as occurred in the current case. Rapid diagnostic tests are 
also insufficiently sensitive, particularly for the diagnosis 
of knowlesi malaria [49, 50], and PCR, although sensitive, 
is limited by expense. Loop-mediated isothermal ampli-
fication (LAMP) assays have been developed recently 
and offer potential as a low–cost sensitive screening 
tool, but have been evaluated in only small numbers of 
Fig. 1 Sequence polymorphisms in the pkdhfr gene fragment in 
Plasmodium knowlesi infections in patients from the transfusion 
recipient’s district, including the transfusion recipient and donor (T1 
and T2). Nineteen polymorphic sites are presented: from left to right 
representing nucleotide positions 36, 90, 101, 135, 192, 240, 252, 271, 
288, 386, 418, 429, 446, 459, 495, 528, 570, 600 and 636 with number-
ing beginning from the first nucleotide of the start codon of pkdhfr 
in the P. knowlesi H strain (PkH1) reference sequence (GeneDB version 
2015-06-18). Dots represent identical nucleotide residues
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patients [51–53]. Larger studies are required to assess the 
potential of this method for screening donated blood for 
malaria parasites.
An additional strategy proposed to prevent TTM in 
endemic countries is default malaria treatment of trans-
fusion recipients [48], although the feasibility of this 
option is limited by the cost of artemisinin-based combi-
nation therapy. Moreover, in a country of low prevalence 
such as Sabah, this strategy would result in significant 
over-treatment of recipients. Recently, a whole blood 
pathogen reduction treatment was shown to reduce 
the incidence of TTM in addition to other transfusion-
transmitted pathogens, demonstrating the potential of 
this technology to enhance safety of blood transfusions in 
malaria-endemic regions [54].
Conclusion
This case demonstrates that acquisition of P. knowlesi 
through blood transfusion may occur, and that clinical 
consequences can be severe. It is possible that thalas-
saemic and/or splenectomized individuals constitute a 
particular risk group for TTM, and may be at high risk 
of severe disease. With a rising incidence of knowlesi 
malaria, further studies are required to determine the 
prevalence of malaria among blood donors in Sabah, 
and the risk of TTM among recipients, in order to guide 
screening strategies for blood transfusion services in the 
region. Finally, clinicians should be aware of the risk of 
TTM in any patient having received a blood transfu-
sion, with post-transfusion febrile illnesses appropriately 
investigated.
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